Vectara Launches Factual Consistency Score Powered by Upgraded Hughes Hallucination Evaluation Model to Enhance Transparency in GenAI Responses
26.3.2024 14:00:00 CET | Business Wire | Press Release
Vectara, the trusted Generative AI product platform, announced the inclusion of a Factual Consistency Score (FCS) for all generative responses based on an evolved version of the groundbreaking Hughes Hallucination Evaluation Model (HHEM)—the #1 hallucination detection model on Hugging Face with 100,000+ downloads since its launch last November. The associated Hallucination Leaderboard is now the industry standard for how LLMs benchmark their average factual consistency. Vectara’s end-to-end Retrieval Augmented Generation-as-a-service (RAGaaS) platform is setting a new standard as an industry-first feature for GenAI response transparency by providing real-time end-to-end RAG observability. This innovative metric provides unprecedented visibility into the factual consistency of summarized responses within Vectara’s RAGaaS platform, empowering users to set personalized thresholds for response acceptance based on a detailed accuracy score.
With average hallucination rates of LLMs on the market ranging from 3% to 16.2%, the risk of unknown inaccuracies in their response remains a major concern, preventing widespread business adoption of this powerful technology. Vectara mitigates this ambiguity for enterprises by providing a Factual Consistency Score grading the likelihood that the generated response is a hallucination or not. Only with a standardized, scientifically calculated method for grading responses can businesses responsibly introduce GenAI into business critical applications. Users have the ability to set thresholds for response acceptance based on a detailed accuracy score, giving product teams the flexibility to act on this information according to their preferences.
Vectara’s Factual Consistency Score is a groundbreaking tool in GenAI, setting a new benchmark for real-time hallucination detection and offering superior performance, affordability, and speed, thus marking a significant leap forward in trust. Its efficiency and effectiveness enable businesses to deploy GenAI into critical product use cases without being worried about exposure to liabilities that might arise from hallucinated responses.
Vectara's Factual Consistency Score equips developers with the capability to refine and enhance a wide range of applications, from internal Q&A systems to the quality of interactions with end consumers. The strength of this score lies in its calibration, making it interpretable as a direct probability—for instance, a score of 0.98 indicates a 98% probability of factual consistency. This contrasts sharply with many contemporary ML classifiers that disregard calibration, thus sacrificing clarity and direct interpretability.
"Integrating Vectara's Factual Consistency Score into the Yobi app will revolutionize how we handle AI transparency and accuracy for business use cases. By providing visibility and accountability into answers provided by our platform, we can stay true to our commitment to responsible AI that enterprises can depend on,” said Ahmed Reza, Founder and CEO of the Yobi app. “As a Co-Innovate Partner with Vectara, we're thrilled to see such advanced technology directly incorporated into the Vectara platform.”
The advanced HHEM that powers the Factual Consistency Score gives greater visibility than previously released open-sourced versions, offering enhanced accuracy and extended language support. This initiative is part of Vectara's commitment to transparency and control, empowering businesses with the autonomy to manage AI responses effectively.
"Just as we were early in pioneering RAG to enhance the relevance and quality of generated content, we are once again at the forefront of responsible AI by being completely open about our efforts to mitigate hallucinations in Generative AI," said Amr Awadallah, co-founder and CEO of Vectara. "By providing our customers with real-time access to factual consistency scores, we're not just engineering trust; we're handing over the control, enabling them to make informed decisions on how to utilize the responses generated by our RAGaaS platform."
About Vectara
Vectara is an end-to-end platform for embedding powerful generative AI features into applications with extraordinary results. As an end-to-end Retrieval Augmented Generation (RAG) platform, Vectara delivers the shortest path to a correct answer/action through a safe, secure, and trusted entry point. Vectara never trains on your data, allowing businesses to embed generative AI capabilities without the risk of data or privacy violations. To learn more, visit vectara.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240326712242/en/
Contact information
Carly Bourne
carly@bulleitgroup.com
423-443-0449
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Newmont Reports 2025 Mineral Reserves of 118.2 Million Gold Ounces and 12.5 Million Tonnes of Copper19.2.2026 22:08:00 CET | Press Release
Newmont Corporation (NYSE: NEM, ASX: NGT, PNGX: NEM) (Newmont or the Company) reported gold Mineral Reserves ("reserves") of 118.2 million attributable ounces at the end of 2025 compared to 134.1 million attributable ounces at the end of 2024, mainly driven by the divestment of assets in 2025. Newmont's portfolio includes significant reserves from other metals, including 12.5 million attributable tonnes of copper reserves and 442 million attributable ounces of silver reserves. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219894602/en/ Percentage of Gold Reserves by Jurisdiction "In 2025, Newmont maintained its position of having the industry's largest gold reserve base, declaring 118 million ounces of reserves, representing decades of production life with meaningful upside," said Natascha Viljoen, Newmont's President and Chief Executive Officer. "Through the disciplined application of technical rigor in our leading expl
Unveiling NVIDIA Solution Center: Grid Dynamics’ Family of AI Solutions to Cut Costs for Retail and Manufacturing19.2.2026 22:05:00 CET | Press Release
Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (Grid Dynamics), a premier AI transformation partner for the Fortune 1000, today announced the launch of its NVIDIA Solution Center. This suite of ready-to-deploy AI applications helps retail and manufacturing enterprises move away from costly, recurring SaaS licenses and subscription fees toward high-performance, NVIDIA-powered solutions. Learn more by reading NVIDIA’s recent announcement. The NVIDIA Solution Center is derived from Grid Dynamics’ proven successful deployments at customers across the retail and manufacturing industries. The suite leverages NVIDIA’s software components including Metropolis, Omniverse, and Nemotron. All solutions offer flexible deployment at the edge, in on-premises datacenters, or in the cloud, enabling customers to achieve an optimal balance between inference cost, latency, privacy, and other operational requirements. The suite covers the following use cases, tailored to the needs of retail and manufacturing
Rimini Street Announces Fiscal Fourth Quarter and Annual 2025 Financial and Operating Results19.2.2026 22:01:00 CET | Press Release
Rimini Street, Inc., (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced results for the 2025 fourth quarter and fiscal year ended December 31, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219293814/en/ Rimini Street Announces Fiscal Fourth Quarter and Annual 2025 Financial and Operating Results “Our fourth quarter results reflect solid execution and continued accelerating sales growth, adjusted for the Oracle PeopleSoft support and services wind down. We grew our core Rimini Support™ subscription billings and launched our next generation Agentic AI ERP solutions that can be easily and quickly deployed over the top of existing ERP Software without the cost or risk of unnecessary ERP Software upgrades, migrations or replatforming,” said
Ares Management Prices European Direct Lending CLO II at Over €300 Million19.2.2026 18:25:00 CET | Press Release
Ares Management Corporation (NYSE: ARES) (“Ares”), a leading global alternative investment manager, announced today the pricing of its second European Direct Lending Collateralized Loan Obligation, Ares European Direct Lending CLO II (“EDL CLO II”), at over €300 million. Consistent with the underlying composition of its predecessor, EDL CLO II is a diversified CLO comprised entirely of directly originated and actively managed loans issued by over 70 middle-market companies predominantly based in Western Europe and primarily operating in resilient industries. The instrument is weighted towards senior-secured floating rate loans and will be rated by S&P and KBRA. Ares believes EDL CLO II is among the first multi-currency middle-market CLOs in Europe. “We are pleased to successfully price our second European Direct Lending CLO in less than 12 months as we continue building on our nearly 20 years of corporate direct lending experience in Europe,” said Michael Dennis, Partner and Co-Head of
Positive Phase 3 Data Demonstrate Potential for ENTYVIO ® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis19.2.2026 18:00:00 CET | Press Release
Takeda (TSE:4502/NYSE:TAK) today announced positive data from the pivotal Phase 3 KEPLER trial, which demonstrated that ENTYVIO® (vedolizumab) can offer the possibility of clinical remission for patients ages 2 and older with moderately to severely active ulcerative colitis (UC), a chronic inflammatory disease of the gastrointestinal tract and one of the two most common types of inflammatory bowel disease.1,2 The results, presented at the 21st Congress of the European Crohn’s and Colitis Organisation (ECCO), show vedolizumab’s promising efficacy and safety profile in a patient population where therapy options remain limited.With KEPLER, Takeda is continuing to generate deeper scientific insights and identify additional patient populations who may benefit from vedolizumab, a cornerstone therapy for adults with ulcerative colitis. Vedolizumab is marketed under the trade name ENTYVIO®*. “Ulcerative colitis is a life-altering diagnosis for young patients and their families, often leaving t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
